PMID- 27751825
OWN - NLM
STAT- MEDLINE
DCOM- 20170321
LR  - 20220408
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 792
DP  - 2016 Dec 5
TI  - MiR-132 plays an oncogenic role in laryngeal squamous cell carcinoma by targeting 
      FOXO1 and activating the PI3K/AKT pathway.
PG  - 1-6
LID - S0014-2999(16)30657-4 [pii]
LID - 10.1016/j.ejphar.2016.10.015 [doi]
AB  - Increasing evidence indicates that the dysregulation of microRNAs is involved in 
      tumor progression and development. The purpose of the present study was to 
      explore the expression of microRNA-132 (miR-132) and its function in laryngeal 
      squamous cell carcinoma (LSCC). The results showed that miR-132 expression was 
      markedly upregulated in LSCC tissues and cell lines. Functional analyses 
      indicated that overexpression of miR-132 enhanced cell proliferation and tumor 
      growth, which resulted in the downregulation of p27 and p21 and the upregulation 
      of cyclin D1. In addition, luciferase activity indicated that miR-132 directly 
      targets FOXO1, and inhibits FOXO1 protein expression in LSCC cells. Further 
      studies revealed that the ectopic expression of FOXO1 effectively reversed the 
      cell growth induced by miR-132. Moreover, miR-132 also activated the PI3K/AKT 
      pathway, which further decreased FOXO1 expression. In conclusion, these findings 
      demonstrated that miR-132 plays an important oncogenic role in LSCC by modulating 
      the PI3K/AKT/FOXO1 pathway at multiple levels, resulting in strong prognostic 
      implication. Therefore, miR-132 might be a potential therapeutic strategy in 
      LSCC.
CI  - Copyright A(c) 2016 Elsevier B.V. All rights reserved.
FAU - Lian, Rong
AU  - Lian R
AD  - Department of Otolaryngol, the First Affiliated Hospital, Xinxiang Medical 
      College, Weihui 453100, Henan, PR China.
FAU - Lu, Baocai
AU  - Lu B
AD  - Department of Otolaryngol, the First Affiliated Hospital, Xinxiang Medical 
      College, Weihui 453100, Henan, PR China.
FAU - Jiao, Lei
AU  - Jiao L
AD  - Department of Otolaryngol, the First Affiliated Hospital, Xinxiang Medical 
      College, Weihui 453100, Henan, PR China.
FAU - Li, Shaomei
AU  - Li S
AD  - Department of Operating Theatre, the First Affiliated Hospital, Xinxiang Medical 
      College, Weihui 453100, Henan, PR China.
FAU - Wang, Huimin
AU  - Wang H
AD  - Department of Otolaryngol, the First Affiliated Hospital, Xinxiang Medical 
      College, Weihui 453100, Henan, PR China.
FAU - Miao, Wenjie
AU  - Miao W
AD  - Department of Otolaryngol, the First Affiliated Hospital, Xinxiang Medical 
      College, Weihui 453100, Henan, PR China.
FAU - Yu, Wenfa
AU  - Yu W
AD  - Department of Otolaryngol, the First Affiliated Hospital, Xinxiang Medical 
      College, Weihui 453100, Henan, PR China. Electronic address: 
      wenfayuxinxiang@sina.com.
LA  - eng
PT  - Journal Article
DEP - 20161015
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Forkhead Box Protein O1)
RN  - 0 (MIRN132 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Base Sequence
MH  - Carcinogenesis/genetics
MH  - Carcinoma, Squamous Cell/*pathology
MH  - Cell Cycle/genetics
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Forkhead Box Protein O1/deficiency/*genetics
MH  - Humans
MH  - Laryngeal Neoplasms/*pathology
MH  - MicroRNAs/*genetics
MH  - Oncogenes/*genetics
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - Signal Transduction/genetics
MH  - Up-Regulation/genetics
OTO - NOTNLM
OT  - FOXO1
OT  - Laryngeal squamous cell carcinoma
OT  - MiR-132
OT  - PI3K/AKT pathway
EDAT- 2016/11/05 06:00
MHDA- 2017/03/23 06:00
CRDT- 2016/11/07 06:00
PHST- 2016/08/21 00:00 [received]
PHST- 2016/10/11 00:00 [revised]
PHST- 2016/10/14 00:00 [accepted]
PHST- 2016/11/05 06:00 [pubmed]
PHST- 2017/03/23 06:00 [medline]
PHST- 2016/11/07 06:00 [entrez]
AID - S0014-2999(16)30657-4 [pii]
AID - 10.1016/j.ejphar.2016.10.015 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2016 Dec 5;792:1-6. doi: 10.1016/j.ejphar.2016.10.015. Epub 2016 
      Oct 15.